文献速递肝病

肝脂肪变性通过小细胞外囊泡抑制细胞胆固醇外流加重动脉粥样硬化

Hepatic steatosis aggravates atherosclerosis via small extracellular vesicle-mediated inhibition of cellular cholesterol efflux.
PubMed 文献 · J Hepatol · 2023-09-05

研究探讨肝脂肪变性来源的小细胞外囊泡(sEVs)在泡沫细胞形成和动脉粥样硬化进展中的作用。机制上,sEVs通过miR-30a-3p靶向ABCA1抑制胆固醇外流,促进泡沫细胞形成和动脉粥样硬化进展;在NAFLD患者中,血清sEVs及sEV-miR-30a-3p与泡沫细胞胆固醇外流水平降低相关。

要点

  • 肝脂肪变性来源的sEVs通过抑制ABCA1介导的胆固醇外流促进泡沫细胞形成和动脉粥样硬化进展。
  • miR-30a-3p富集于肝脂肪变性来源的sEVs中,直接靶向ABCA1的3'非翻译区抑制其表达和胆固醇外流。
  • NAFLD患者血清sEVs及sEV-miR-30a-3p表达与泡沫细胞胆固醇外流水平降低相关。

核心结论

  • 肝脂肪变性来源的sEVs通过miR-30a-3p/ABCA1轴促进泡沫细胞形成并促进动脉粥样硬化形成。
  • 减少肝脂肪变性来源的sEVs分泌或靶向miR-30a-3p可能是减缓NAFLD驱动动脉粥样硬化进展的潜在治疗途径。

研究设计与样本

  • 基础实验研究结合NAFLD患者横断面研究。
  • 分离并表征肝脂肪变性来源的sEVs,采用miRNA深度测序鉴定sEVs中的功能性miRNA。
  • 在ApoE-/-小鼠中进行巨噬细胞特异性Abca1敲除、肝细胞特异性Rab27a敲除及antagomiR-30a-3p干预实验。
  • 对NAFLD患者进行横断面研究以验证上述发现。

主要发现

  • 肝脂肪变性来源的sEVs通过抑制ABCA1介导的胆固醇外流促进巨噬细胞来源的泡沫细胞形成和动脉粥样硬化进展。
  • ApoE-/-小鼠巨噬细胞特异性敲除Abca1可消除肝脂肪变性来源sEVs对动脉粥样硬化进展的作用。
  • ApoE-/-小鼠肝细胞特异性敲除Rab27a可显著改善高脂高胆固醇饮食诱导的动脉粥样硬化进展。
  • miRNA深度测序显示miR-30a-3p富集于肝脂肪变性来源的sEVs中,miR-30a-3p直接靶向ABCA1的3'非翻译区抑制ABCA1表达和胆固醇外流。
  • antagomiR-30a-3p治疗可显著减轻高脂高胆固醇饮食喂养ApoE-/-小鼠的动脉粥样硬化进展。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: While it is recognized that non-alcoholic fatty liver disease (NAFLD) is associated with cardiovascular disease (CVD), how NAFLD affects the development and progression of CVD remains unclear and debatable. Hence, we aimed to determine the role of steatotic hepatocyte-derived small extracellular vesicles (sEVs) in foam cell formation and atherosclerosis progression. METHODS: sEVs from steatotic hepatocytes were isolated and characterized. MicroRNA (miRNA) deep sequencing was utilized to identify functional miRNA in sEVs. Lastly, we conducted a cross-sectional study on patients with NAFLD to validate these findings. RESULTS: Treatment of sEVs from steatotic hepatocytes promoted macrophage-derived foam cell formation and atherosclerosis progression via inhibition of ABCA1-mediated cholesterol efflux. Macrophage-specific deletion of Abca1 in ApoE-/- mice abolished the role of steatotic hepatocyte-derived sEVs in atherosclerosis progression. In addition, hepatocyte-specific deletion of Rab27a, which is the key GTPase regulating sEV release, significantly ameliorated high-fat, high-cholesterol diet-induced atherosclerosis progression in ApoE-/- mice. The miRNA deep sequencing results showed that miR-30a-3p was enriched in sEVs from steatotic hepatocytes. miR-30a-3p directly targeted the 3' untranslated region of ABCA1 to inhibit ABCA1 expression and cholesterol efflux. Treatment with antagomiR-30a-3p significantly attenuated atherosclerosis progression in high-fat, high-cholesterol diet-fed ApoE-/- mice. Moreover, serum sEVs from patients with NAFLD and sEV-miR-30a-3p expression were associated with decreased cholesterol efflux levels in foam cells. CONCLUSION: Steatotic hepatocyte-derived sEVs promote foam cell formation and facilitate atherogenesis via the miR-30a-3p/ABCA1 axis. Reducing sEV secretion by steatotic hepatocytes or targeting miR-30a-3p may be potential therapeutic approaches to slow the progression of NAFLD-driven atherosclerosis. IMPACT AND IMPLICATIONS: The presence of hepatic steatosis is strongly correlated with the risk of cardiovascular disease and cardiovascular events, yet the molecular mechanisms linking steatosis to progression of atherosclerosis are unclear. Herein, we identified small extracellular vesicles from steatotic hepatocytes as a trigger that accelerated the progression of atherosclerosis. Steatotic hepatocyte-derived small extracellular vesicles promoted foam cell formation via the miR-30a-3p/ABCA1 axis. Our findings not only provide mechanistic insight into non-alcoholic fatty liver disease-driven atherosclerosis but also provide potential therapeutic targets for patients with atherosclerosis.

来源:J Hepatol,查看原文。版权归原作者所有。

引用

  1. Chen X, Chen S, Pang J, et al. Hepatic steatosis aggravates atherosclerosis via small extracellular vesicle-mediated inhibition of cellular cholesterol efflux. J Hepatol. 2023. PMID: 37678722. doi:10.1016/j.jhep.2023.08.023

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。